#retatrutide Retatrutide: Understanding Its Triple Receptor Activation and Clinical Impact Retatrutide for Weight Loss: TRIUMPH-1

p 9.5% Baseline characteristics Average age 54 years Average BMI - 36 Average weight - 220 lbs (100 kg) Type 2 diabetes - 58% Average NAFLD activity score - 5.3 Liver fibrosis stage: F2 - 43% | F3 - 57% Randomized treatment groups Group 1 (47 patients): Tirzepatide 5 mg once weekly Group 2 (47patients): Tirzepatide 10 mg once weekly Group 3 (48 patients): Tirzepatide 15 mg once weekly Group 4 (48 patients): Placebo Therapy was initiated at 2.5 mg, and patients were titrated to their assigned dose in 2.5 mg increments every 4 weeks Resolution of MASH (defined as no steatotic liver disease [steatosis score of 0] or simple steatosis [a steatosis score of 1, 2, or 3] without steatohepatitis and an inflammation score of 0 or 1 and a ballooning score of 0), without worsening of fibrosis (defined as no increase in the fibrosis stage) at week 52 Primary outcome: Results In this phase 2 trial involving participants with MASH and moderate or severe fibrosis, treatment with tirzepatide for 52 weeks was more effective than placebo with respect to resolution of MASH without worsening of fibrosis

Glutathione typically protects hair color by neutralizing hydrogen peroxide

Animal care and experimental procedures were approved by the Animal Experimentation Ethics Committee of Malaga University and authorised by the government of Andaluca, Spain (project no

Long-time followers of the Jay Campbell ecosystem KNOW Ive been beating the drum on Retatrutide for awhile now

Tirzepatide performs measurably better here

& Garbuglia, A